Topical Antineoplastics

Topical antineoplastics are cancer-fighting medications applied directly to the skin. Instead of being swallowed as a pill or injected into a vein, these drugs are rubbed, dabbed, or spread onto abnormal or cancerous skin tissue. They work locally — meaning they target the problem area without significantly affecting the rest of your body.

What Are Topical Antineoplastics?

The word antineoplastic comes from Greek: anti (against) + neo (new) + plasma (formation). It simply means against abnormal cell growth. When a medication is topical, it means it is applied to the surface of the body — in this case, the skin.

Topical antineoplastics are used when cancer or pre-cancer is limited to the outer layers of the skin. They are an alternative to surgery or radiation for surface-level skin conditions, and they can be very effective when used correctly.

These medications are available in several forms:

• Creams — most common, easy to spread on skin
• Gels — absorb quickly, often preferred for oily or scalp areas
• Solutions — liquid applied with a dropper or applicator
• Ointments — thicker, longer-lasting on the skin

How Do Topical Antineoplastics Work?

Different topical antineoplastics work through different mechanisms, but all of them target abnormal cells in some way. Here are the main methods:

Disrupting Cell Division

Some medications interfere with the ability of abnormal cells to copy their DNA and divide. Because cancer and pre-cancer cells divide much faster than normal cells, these drugs hit them harder. The abnormal cells cannot reproduce and eventually die.

Triggering the Immune System

Some topical treatments activate the body’s own immune defenses. They signal the immune system to recognize and destroy abnormal cells, almost like calling in the body’s natural army.

Blocking Cellular Enzymes

Certain drugs block specific enzymes (proteins) that cancer cells rely on to survive and grow. Without these enzymes, the cells cannot function and they die off.

Inducing Programmed Cell Death

All healthy cells have a built-in self-destruct mechanism called apoptosis. Cancer cells often disable this. Some topical antineoplastics reactivate it, forcing abnormal cells to die naturally.

What Conditions Do They Treat?

Topical antineoplastics are prescribed for a range of skin conditions, from pre-cancerous lesions to actual skin cancers:

Condition	What It Is	Risk Level
Actinic Keratosis (AK)	Rough, scaly patches caused by years of sun damage. Considered pre-cancerous.	Pre-cancerous — can develop into squamous cell carcinoma if untreated
Basal Cell Carcinoma (BCC)	The most common type of skin cancer. Grows slowly and rarely spreads.	Low-grade cancer — superficial types are treated topically
Squamous Cell Carcinoma in Situ (Bowen’s Disease)	An early form of squamous cell carcinoma confined to the top layer of skin.	Early-stage cancer — topical treatment is often effective
Cutaneous T-Cell Lymphoma (CTCL)	A rare type of non-Hodgkin’s lymphoma that affects the skin.	Skin-based lymphoma — requires specialist care
Kaposi’s Sarcoma	A cancer that causes lesions on the skin, often seen in immunocompromised patients.	Moderate — topical treatment for localized lesions
Mycosis Fungoides	The most common form of CTCL, causing red, itchy, scaly patches.	Chronic skin lymphoma — often managed long-term

Types of Topical Antineoplastics

There are several different categories of topical antineoplastics, each working through a different mechanism:

Antimetabolites

These drugs mimic nutrients that cells need to divide. When a cell absorbs the drug instead of the real nutrient, its ability to copy DNA is disrupted and it dies. Fluorouracil (5-FU) is the most well-known example.

Immune Response Modifiers

These stimulate the local immune system to fight abnormal cells. Imiquimod is the primary drug in this category. It does not directly kill cells — instead, it wakes up the immune system to do the job.

Retinoids

Derived from vitamin A, retinoids regulate how skin cells grow and mature. Bexarotene gel is a retinoid used specifically for cutaneous T-cell lymphoma. They help normalize abnormal cell behavior and promote healthy cell turnover.

Enzyme Inhibitors (EGFR Inhibitors)

These block a protein called the epidermal growth factor receptor (EGFR), which some cancer cells use to grow. By blocking this signal, cell growth slows or stops.

Dihydrofolate Reductase Inhibitors

These block an enzyme cells need to make DNA building blocks. Methotrexate in topical form falls into this category, though it is used less commonly than the oral form.

Common  Topical antineoplastics Medications: Names, Forms, and Uses

Generic Name	Brand Name(s)	Form	Main Uses	How Often Applied
Fluorouracil (5-FU)	Carac, Efudex, Tolak, Fluoroplex	Cream, Solution	Actinic keratosis, superficial basal cell carcinoma, Bowen’s disease	Once or twice daily for 2–6 weeks
Imiquimod	Aldara (5%), Zyclara (2.5%, 3.75%)	Cream	Actinic keratosis, superficial basal cell carcinoma, genital warts	2–5 times per week for 6–16 weeks
Ingenol Mebutate	Picato	Gel	Actinic keratosis	Once daily for 2–3 consecutive days only
Bexarotene	Targretin	Gel	Cutaneous T-cell lymphoma (CTCL), mycosis fungoides	Every other day, increasing to twice daily
Mechlorethamine (Nitrogen Mustard)	Valchlor	Gel	Mycosis fungoides (stage IA and IB)	Once daily
Diclofenac Sodium	Solaraze	Gel	Actinic keratosis (mild to moderate)	Twice daily for 60–90 days
Tirbanibulin	Klisyri	Ointment	Actinic keratosis on the face or scalp	Once daily for 5 consecutive days

How to Apply Topical Antineoplastics

Before You Apply

• Clean your hands well with soap and water both before applying the medication and once you’ve finished.
• Clean and dry the treatment area gently. Do not scrub.
• Avoid applying to broken, irritated, or infected skin unless directed by your doctor.
• Do not apply near the eyes, nostrils, mouth, or genitals unless specifically instructed.

During Application

• Use the exact amount prescribed — more is not better and can cause severe reactions.
• Apply a thin layer and gently rub in, or dab onto lesions as instructed.
• Use a non-metal applicator, gloved finger, or cotton swab for certain medications (especially mechlorethamine/nitrogen mustard).
• Allow the medication to dry before covering with clothing.
• Do not use bandages or occlusive dressings unless told to do so — covering the area can dramatically increase absorption and side effects.

After Application

• Wash your hands again thoroughly.
• Avoid touching your face, especially your eyes, until hands are clean.
• Do not wash the treated area for at least 6 hours after application (timing varies by drug — check your specific instructions).
• Avoid sun exposure to the treated area. Use sunscreen and protective clothing.

Side Effects

Topical antineoplastics are powerful medications, and skin reactions at the application site are expected and normal — in fact, for some drugs like fluorouracil and imiquimod, a strong skin reaction is a sign that the medication is working.

Common Local Reactions (at the application site)

Side Effect	Description	When It Typically Occurs
Redness (Erythema)	Skin becomes red and inflamed	Within the first 1–2 weeks
Swelling	Mild puffiness around the treated area	First 1–3 weeks
Burning or Stinging	Sensation of heat or tingling after application	Immediately after application
Itching	Pruritus at the treatment site	Throughout treatment
Crusting and Scabbing	Treated skin forms a crust or scab as it heals	Weeks 2–4
Erosion or Ulceration	Surface of the skin may break down temporarily	Peak reaction, weeks 2–4
Skin Peeling	Flaking or peeling of the treated skin	During and after treatment
Hyperpigmentation	Darkening of skin in the treated area	During or after treatment

Less Common Systemic Side Effects

Because topical antineoplastics are absorbed only minimally through the skin, systemic (whole-body) side effects are rare but possible, especially if the drug is applied to large areas:

• Flu-like symptoms (more common with imiquimod)
• Fatigue or tiredness
• Headache
• Nausea (uncommon)

Serious Side Effects — Contact Your Doctor Immediately If You Experience:

• Severe pain that is not manageable
• Pus, discharge, or signs of infection in the treated area
• Blistering beyond the treatment site
• High fever above 38.5°C (101.3°F)
• Extreme swelling especially near the eyes or mouth
• Severe allergic reaction: difficulty breathing, hives, swollen face or throat

8. Precautions and Warnings

Pregnancy and Breastfeeding

Most topical antineoplastics should not be used during pregnancy. Fluorouracil and mechlorethamine in particular carry significant risks to a developing baby. Always tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding before starting any of these medications.

Sun Sensitivity

Many of these drugs make the treated skin extremely sensitive to sunlight. Even brief sun exposure can cause severe burns or worsen reactions. During treatment:

• Avoid direct sunlight on treated areas
• Apply sunscreen (SPF 30 or higher) daily
• Wear protective clothing and a wide-brimmed hat

Do Not Use on Certain Areas

Unless specifically directed by your doctor, avoid applying to:

• Eyelids or the area directly around the eyes
• Inside the nostrils
• Inside the mouth or lips
• Open wounds or severely irritated skin

Keep Away from Children and Pets

Topical antineoplastics are hazardous medications. Keep them locked away and out of reach. Do not allow children or pets to touch tubes, applicators, or treated skin areas.

Cosmetics and Skin Products

Do not apply makeup, lotions, sunscreen, or other skincare products to the treatment area immediately before or after applying the medication. Ask your doctor how long to wait between products.

Topical Antineoplastics and Drug Interactions

Because topical antineoplastics are applied to the skin and absorbed minimally, drug interactions are less common than with oral medications. However, some interactions are known:

Drug or Substance	Interacts With	What Can Happen
Blood thinners (warfarin)	Fluorouracil (5-FU)	5-FU may increase the effect of warfarin, raising bleeding risk
Other topical skin products	All topical antineoplastics	Can alter absorption or cause additive irritation
Immunosuppressants	Imiquimod	May reduce effectiveness since imiquimod relies on the immune system
Photosensitizing medications	Most topical antineoplastics	Increased risk of severe sunburn or phototoxic reaction
Vitamin A supplements or high-dose vitamins	Bexarotene gel	Additive toxicity risk
DEET-containing insect repellents	Mechlorethamine (Valchlor)	Increased skin absorption and irritation

What Results Should You Expect?

Timeline of Treatment

Treatment timelines vary significantly depending on the drug and the condition being treated. Here is a general overview:

Medication	Typical Treatment Duration	When to Expect Healing
Fluorouracil (5-FU)	2 to 6 weeks of application	Full healing 4–8 weeks after stopping
Imiquimod (Aldara 5%)	6 to 16 weeks	Improvement during treatment; full response 12–16 weeks
Imiquimod (Zyclara)	2 cycles of 2 weeks each	Assessment at the end of each cycle
Ingenol Mebutate	2 to 3 days only	Lesion resolution within 4–8 weeks
Mechlorethamine (Valchlor)	Long-term (months to years)	Gradual improvement over several months
Tirbanibulin (Klisyri)	5 days	Assessment at 8 weeks

What the Skin Goes Through

During treatment, especially with fluorouracil or imiquimod, the skin often goes through a predictable sequence:

1. Week 1–2: Redness and mild irritation begin
2. Week 2–4: Peak reaction — significant redness, swelling, crusting, possible erosion. This looks alarming but is often a sign the drug is working.
3. After treatment ends: Gradual healing, with new healthy skin appearing over several weeks
4. Final result: Improved or clear skin, often with less visible sun damage in surrounding areas

Success Rates

When used correctly on appropriate lesions:

• Fluorouracil clears actinic keratoses in approximately 50–85% of treated lesions
• Imiquimod 5% clears superficial basal cell carcinoma in approximately 75–80% of cases
• Ingenol mebutate achieves complete clearance in approximately 42–54% of actinic keratosis lesions
• Tirbanibulin achieves complete clearance in approximately 44–54% of lesions

Storage and Handling

How to Store

• Store at room temperature (59–77°F / 15–25°C) unless otherwise stated on the label
• Do not freeze creams or gels
• Keep away from heat, direct light, and humidity — do not store in the bathroom
• Keep caps and lids tightly closed when not in use
• Check the expiration date and do not use expired medication

Safe Disposal

Topical antineoplastics are classified as hazardous drugs. Do not throw them in regular household trash or flush them down the toilet. Instead:

• Return unused medication to a pharmacy take-back program
• Ask your pharmacist about proper disposal in your area
• If no take-back is available, some medications have specific FDA-approved disposal instructions — check the patient information leaflet

Handling Precautions

• Wear disposable gloves when applying mechlorethamine (Valchlor) — it can cause serious skin reactions on unintended areas
• Wash hands thoroughly before and after applying any topical antineoplastic
• Avoid skin-to-skin contact between the treated area and another person’s skin until the medication has fully absorbed

12. Frequently Asked Questions

Will topical antineoplastics leave scars?

Generally, no. One of the advantages of topical treatment over surgery is that it typically heals with minimal or no scarring. The cosmetic outcome is often very good, particularly on the face. However, individual healing varies.

Can I use makeup during treatment?

It depends on the treated area and your doctor’s advice. In most cases, you should avoid applying cosmetics directly over the treatment area during active therapy. Ask your dermatologist when it is safe to resume normal skincare and makeup routines.

Is the severe skin reaction during fluorouracil treatment normal?

Yes. A reaction involving redness, crusting, and even open sores is a normal and expected part of fluorouracil treatment. It indicates that the drug is destroying pre-cancerous cells. The skin heals after the treatment course ends. However, if you are in severe pain or notice signs of infection, contact your doctor.

Can I stop the treatment early if my skin clears up?

No. Complete the full prescribed course even if the skin looks clear or normal. Pre-cancerous cells may still be present but not yet visible. Stopping early increases the risk of the condition coming back.

Can I exercise or sweat during treatment?

Excessive sweating can wash off the medication before it has been absorbed and may spread it to unintended areas. It is generally advisable to avoid vigorous exercise immediately before or after application. Ask your doctor for specific guidance based on the medication you are using.

What should I do if I accidentally get the medication in my eyes?

Rinse your eye immediately and thoroughly with clean water for at least 15 minutes and seek medical attention. Topical antineoplastics can cause serious eye injury.

Can I drink alcohol during treatment?

Alcohol is not known to directly interact with most topical antineoplastics. However, heavy alcohol use can impair skin healing.

What happens if I apply too much?

Applying more than prescribed will not make the treatment faster or more effective — it will cause more severe and potentially dangerous skin reactions. If you accidentally apply too much, wipe off the excess gently and rinse the area with water. Contact your doctor or poison control if the reaction seems severe.

Are these medications covered by insurance?

Coverage varies by country, insurance plan, and specific medication. Many topical antineoplastics are approved treatments and are covered, but co-pays can be significant for branded medications. Ask your pharmacist about generic options, which are often much less expensive and equally effective.

Summary

Topical antineoplastics are an important and well-established category of medication for treating pre-cancerous and superficial cancerous skin conditions. They allow targeted treatment directly where it is needed, minimizing effects on the rest of your body.

Key takeaways:

• They work by killing or slowing the growth of abnormal skin cells
• They are used for actinic keratoses, superficial skin cancers, and some skin lymphomas
• Common examples include fluorouracil (5-FU), imiquimod, and mechlorethamine
• Skin reactions during treatment are expected and are a sign the medication is working
• Always follow your doctor’s exact instructions for application, frequency, and duration
• Sun protection is essential during and after treatment
• Complete the full treatment course, even if your skin looks clear
• Store and dispose of these medications safely — they are classified as hazardous drugs

Sources & References

1. Bastiaens, M.T. and Kessels, J.P.H.M. (2014) ‘Topical pharmacotherapy for skin cancer: part I. Actinic keratosis and basal cell carcinoma’, Journal of Drugs in Dermatology, 13(2), pp. 141–146. Available at: PubMed
2. Chovatiya, R. and Silverberg, J.I. (2019) ‘Topical treatments for skin cancer’, Expert Review of Anticancer Therapy, 19(12), pp. 1029–1044. Available at: PubMed
3. Lallas, A. et al. (2023) ‘Gel formulations for topical treatment of skin cancer: a review’, Gels, 9(4), p. 262. Available at: PMC
4. Navarro-Triviño, F.J. et al. (2026) ‘Biomaterials for improving skin penetration in treatment of non-melanoma skin cancer’, Pharmaceutics, 18(1), p. 55. Available at: PMC
5. Nisticò, S.P. et al. (2024) ‘Topical pharmacological treatment of actinic keratoses’, Dermatologic Therapy, 37(4), p. e15321. Available at: PMC
6. Renganathan, R. et al. (2023) ‘Recent advancements in skin cancer treatment: a critical review’, Exploration of Medicine, 4, p. 1001178. Available at: Exploration
7. Tampucci, S. (2024) ‘Skin cancer: new formulation strategies for topical treatment’, Journal of Clinical & Experimental Dermatology Research (conference abstract). Available at: SciTechnol
8. Urbatsch, A. et al. (2020) ‘Topical treatments for non-melanoma skin cancer’, Journal of Dermatological Treatment, 31(8), pp. 795–805. Available at: PubMed
9. Zhang, H. et al. (2025) ‘Drug repurposing and nanotechnology for topical skin cancer therapy’, ACS Pharmacology & Translational Science, 8(2), pp. 123–140. Available at: ACS Publications